Evidence map›Paper›PMID 35682755›Full record

ArticleInternational journal of molecular sciences2022

De Novo Development of Mitochondria-Targeted Molecular Probes Targeting Pink1.

Shulamit Fluss Ben-Uliel, Faten Habrat Zoabi, Moriya Slavin, Hadas Sibony-Benyamini, Nir Kalisman, Nir Qvit

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Noncoding RNA as potential therapeutics to rescue mitochondrial dysfunction in cardiovascular diseases.American journal of physiology. Heart and circulatory physiology · 2025
    Pooled it
  2. Article
  3. Special Issue "Peptides for Health Benefits 2021".International journal of molecular sciences · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shulamit Fluss Ben-UlielThe Azrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Safed 1311502, Israel.
Faten Habrat ZoabiThe Azrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Safed 1311502, Israel.
Moriya SlavinInstitute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 9190401, Israel.
Hadas Sibony-BenyaminiThe Azrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Safed 1311502, Israel.
Nir KalismanInstitute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 9190401, Israel.ORCID 0000-0003-1615-7136
Nir QvitThe Azrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Safed 1311502, Israel.ORCID 0000-0002-2578-1048
Bar-Ilan University · ILHebrew University of Jerusalem · IL

Funding

Israel Science Foundation 935/20
6 · The paper itself

Abstract

Mitochondria play central roles in maintaining cellular metabolic homeostasis, cell survival and cell death, and generate most of the cell's energy. Mitochondria maintain their homeostasis by dynamic (fission and fusion) and quality control mechanisms, including mitophagy, the removal of damaged mitochondria that is mediated mainly by the Pink1/Parkin pathway. Pink1 is a serine/threonine kinase which regulates mitochondrial function, hitherto many molecular mechanisms underlying Pink1 activity in mitochondrial homeostasis and cell fate remain unknown. Peptides are vital biological mediators that demonstrate remarkable potency, selectivity, and low toxicity, yet they have two major limitations, low oral bioavailability and poor stability. Herein, we rationally designed a linear peptide that targets Pink1 and, using straightforward chemistry, we developed molecular probes with drug-like properties to further characterize Pink1. Initially, we conjugated a cell-penetrating peptide and a cross-linker to map Pink1's 3D structure and its interaction sites. Next, we conjugated a fluorescent dye for cell-imaging. Finally, we developed cyclic peptides with improved stability and binding affinity. Overall, we present a facile approach to converting a non-permeable linear peptide into a research tool possessing important properties for therapeutics. This is a general approach using straightforward chemistry that can be tailored for various applications by numerous laboratories.

Indexed as

Molecular ProbesProtein KinasesMitochondriaMitophagyProtein Serine-Threonine KinasesUbiquitin-Protein LigasesMolecular ProbesProtein KinasesProtein Serine-Threonine KinasesUbiquitin-Protein Ligasesbackbone cyclizationbioactive peptidesmitochondriamitophagymolecular probespeptidomimeticsPink1protein-peptide interactionsprotein-protein interactionstherapeutic peptides

Identifiers

PMID35682755
PMCPMC9181014
OpenAlexW4281687041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.